ACURX PHARMACEUTICALS ($ACXP) posted quarterly earnings results for Q1 2026 on Tuesday, May 12th. The company reported earnings of -$0.62 per share, beating estimates of -$0.65 by $0.03. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $ACXP stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ACURX PHARMACEUTICALS Hedge Fund Activity
We have seen 11 institutional investors add shares of ACURX PHARMACEUTICALS stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 41,427 shares (+inf%) to their portfolio in Q4 2025, for an estimated $103,153
- VANGUARD GROUP INC added 23,280 shares (+inf%) to their portfolio in Q4 2025, for an estimated $57,967
- CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. added 20,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $74,200
- NORTHERN TRUST CORP added 16,914 shares (+inf%) to their portfolio in Q4 2025, for an estimated $42,115
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 16,815 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $41,869
- GEODE CAPITAL MANAGEMENT, LLC added 12,417 shares (+inf%) to their portfolio in Q4 2025, for an estimated $30,918
- JANE STREET GROUP, LLC added 10,743 shares (+inf%) to their portfolio in Q4 2025, for an estimated $26,750
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
